

Comorbidities that increase risk for severe acute COVID-19 in pediatric population

Alfredo Tagarro García^{1,2}, Irati Gastesi García², Sara Villanueva Medina², Andrea Ramírez Varela³, María Lucía Mesa Rubio⁴, Pablo Vasquez Hoyos⁵, Gabriela Friedrich³, Melisa Naranjo Vanegas⁴, Sonia Restrepo Gualteros⁵, Olga Lucía Vaquero⁶, Luz Marina Mejía⁷, Carlos Álvarez⁸, Inés Leoz Gordillo⁹, Cristina Calvo Rey¹⁰, Cristina Epalza Errondo¹¹, Toni Soriano Arandes¹², Ana Menasalvas Ruiz¹³, Marisa Navarro Gómez¹⁴, Mercedes Herranz Aguirre¹⁵, Victoria Fumadó Pérez¹⁶, Marthe le Prevost¹⁷, Carlo Giaquinto¹⁸, Cinta Moraleda Redecilla²

¹. Fundación para la Investigación del Hospital Universitario Infanta Sofía y del Henares, Madrid, España, Universidad Europea de Madrid ². Fundación de Investigación Biomédica Hospital 12 de Octubre. Instituto de Investigación 12 de Octubre (imas12), Madrid, España, ³. Universidad de los Andes, Bogotá, Colombia. ⁴. Universidad Nacional de Colombia, Bogotá, Colombia, ⁵. Fundación Santa Fe, Bogotá, Colombia, ⁶. Clínica Infantil Colsubsidio, Cundinamarca, Colombia, ⁷. Instituto Roosevelt, Cundinamarca, Colombia, ⁸. Clínicas colsanitas, Bogotá, Colombia, ⁹. Hospital Niño Jesús, Madrid, España, ¹⁰. Hospital La Paz, Madrid, España, ¹¹. Hospital Universitario 12 de Octubre, Madrid, España, ¹². Hospital Universitario Vall d'Hebron, Barcelona, España, ¹³. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, España, ¹⁴. Hospital General Universitario Gregorio Marañón, Madrid, España, ¹⁵. Complejo Hospitalario de Navarra, Pamplona, España, ¹⁶. Hospital Sant Joan de Déu, Barcelona, España, ¹⁷. Medical Research Council, ¹⁸. Fondazione PENTA Onlus, Padua, Italia

BACKGROUND

- Little is understood about which comorbidities are associated with severe outcomes in children hospitalized with acute COVID-19. Some confusion lies especially for cancer or diabetes.

METHODS

- Data from 2 multicenter prospective cohort studies of hospitalized children (aged 0-18 years) with confirmed SARS-CoV-2 in Spain and Colombia were combined for this analysis.
- Data were obtained from 116 hospitals.
- Outcome was classified as (in decreasing order of severity): death, mechanical ventilation (MV), pediatric intensive care unit (PICU) admission, high flow/CPAP, oxygen therapy with nasal prong (NP) and hospitalization without respiratory support.
- Risk factors for severity, adjusting for age and gender, were identified using multinomial logistic regression and a backwards selection process.

RESULTS

- A total of 1,753 patients were included, 734 (41.8%) in Spain and 1,019 (58.1%) in Colombia. The most frequent comorbidities were asthma (9.0%), chronic neurological disorder (NRL) (7.4%), immunosuppressive medication (7.2%), malignant neoplasms (5.4%), and chronic lung disease (not asthma) (CLD) (4.5%).
- Asthma was associated with a significantly increased risk of death (OR: 4.17; 95%CI 1.34-12.97), MV (OR: 7.94 (3.59-17.56)), PICU admission (OR: 3.37 (1.91-5.96)), high flow/CPAP (OR: 6.65 (2.69-16.46)), and NP (OR: 3.85 (2.57-5.77)) compared to hospitalization without respiratory support.

Asthma, chronic neurological, cardiac and lung disease were consistently associated with multiple severe outcomes of COVID-19 – not cancer or diabetes

- NRL was associated with increased risk of death (OR: 7.34 (3.01-17.90)), MV (OR: 3.07 (1.20-7.82)) and high flow/CPAP (OR: 4.36 (1.68-11.29)).
- CLD was associated with increased risk of death (OR: 6.22 [2.28-16.94]) and NP (OR: 3.1 (1.74-5.58))
- Chronic cardiac disease was associated with increased risk of MV (OR: 5.21 (1.76-15.41)) and PICU (OR: 2.78 (1.27-6.08)).
- Risks of death (OR: 4.49 (2.03-9.05)), MV (OR: 2.97 (1.52-5.81)), PICU (OR: 4.27 (2.89-6.33)), and NP (OR: 4.67 (3.64-5.99)) were higher in the Colombia Cohort.

CONCLUSIONS Asthma, chronic neurological, cardiac and lung disease; and belonging to the Colombia cohort were consistently associated with multiple severe outcomes of COVID-19. Cancer and diabetes association with selected endpoints rather than with most endpoints may be more related to the baseline disease than with the actual COVID-19.

ADDITIONAL KEY INFORMATION Funding

- The ORCHESTRA project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101016167. The views expressed in this abstract are the sole responsibility of the author and the Commission is not responsible for any use that may be made of the information it contains
- This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project "20/00995" and co-funded by the European Union
- EPICO-Colombia: Organización Panamericana de la Salud
- EPICO-AEP: Asociación Española de Pediatría
- Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre.
- Fundación para la Investigación Biomédica e Innovación Hospital Universitario Infanta Sofía y Henares University Hospital (FIIB HUIS HHEN).
- Universidad Europea de Madrid. Madrid (Spain)

Comorbidity	Death	MV	PICU	CPAP/High flow therapy	O2
Chronic cardiac disease	1.36 [0.29;6.49]	5.21 [1.76;15.41]	2.78 [1.27;6.08]	3.28 [0.87;12.32]	1.73 [0.92;3.26]
Chronic pulmonary disease	6.22 [2.28;16.94]	2.60 [0.73;9.22]	1.14 [0.41;3.17]	2.97 [0.83;10.59]	3.12 [1.74;5.58]
Asthma or recurrent wheezing	4.17 [1.34;12.97]	7.94 [3.59;17.56]	3.37 [1.91;5.96]	6.65 [2.69;16.46]	3.85 [2.57;5.77]
Chronic neurological disorder	7.34 [3.01;17.90]	3.07 [1.20;7.82]	1.52 [0.79;2.96]	4.36 [1.68;11.29]	1.10 [0.68;1.76]
Malignant Neoplasm	5.03 [2.09;12.12]	0.00 [-;-]	1.15 [0.59;2.21]	1.00 [0.22;4.41]	0.15 [0.06;0.37]
Chronic hematologic disease	2.67 [0.85;8.37]	1.44 [0.32;6.40]	0.68 [0.27;1.69]	0.75 [0.10;5.86]	0.35 [0.15;0.80]
Diabetes	2.99 [0.29;30.70]	0.00 [0.00;0.00]	5.67 [1.84;17.47]	0.00 [-;-]	1.19 [0.33;4.24]

Multivariable association between comorbidities on the odds of each outcome (compared to hospitalization without respiratory support). Table 1. Color gradient across endpoints (red: risk factors, green: protective)

